Trial
NCT04092179
Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University Health Network, Toronto
Collaborators
Celgene; AbbVie
Condition
Acute Myeloid Leukemia
Intervention
Enasidenib
Why stopped
Insufficient Funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-01-24